MONTREAL--(BUSINESS WIRE)--Dec. 16, 2005--MethylGene Inc. (TSX:MYG) a biopharmaceutical company, today disclosed in two posters, preclinical results demonstrating the potential use of an isotype-selective histone deacetylase (HDAC) inhibitor in human fungal infections at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington DC. The Company described data from in vitro and in vivo experiments, which demonstrate that: